Indaptus Therapeutics, Inc.
8.44%
11,250,000
1857044
Jun 23, 2026
Jun 26, 2026, 08:00 PM
Reporting Persons (1)
| Name | Type | % of Class | Aggregate | Sole Voting | Shared Voting |
|---|---|---|---|---|---|
| Dai Junyi | Individual | 8.44% | 11,250,000 | 11,250,000 | 0 |
Disclosure Items (7)
Common Stock, par value $0.01 per share
Indaptus Therapeutics, Inc.
c/o Indaptus Therapeutics, Inc., New York, NY, 10019
Mr. Junyi Dai, an individual.
Mr. Dai's address is c/o Indaptus Therapeutics, Inc., 3 Columbus Circle, 15th Floor, New York, NY, 10019.
Mr. Dai's present principal occupation is the chief executive officer and chairman of Indaptus Therapeutics, Inc.
During the last five years, Mr. Dai has not been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction, which as a result of such proceeding, was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, United States federal or state securities laws or finding any violation with respect to such laws.
Mr. Dai is a citizen of the Australia.
The Series AAA Preferred Stock was purchased by Mr. Dai pursuant to the Securities Purchase Agreement, dated as of March 19, 2026 (the "Purchase Agreement") between David Lazar, Yun Yao, Sino Lion Ventures Limited, Junyi Dai, Ting Yang, and Lina Deng. The Purchase Agreement closed on March 23, 2026. Mr. Dai used personal funds in the aggregate amount of $1,156,642.43 to fund his purchase.
The information contained on the cover pages to this Schedule 13D is incorporated herein by reference. As of the date hereof, there are 133,242,324 shares of Common Stock outstanding as of June 24, 2026, as calculated based on the Issuer's Form 8-K filed with the SEC on June 24, 2026.
The following table sets forth the number of Common Stock as to which the Reporting Person has (i) the sole power to vote or direct the vote, (ii) shared power to vote or to direct the vote, (iii) sole power to dispose or to direct the disposition, or (iv) shared power to dispose or to direct disposition:
The Reporting Person have not effected any transaction in the shares of Common Stock during the past 60 days.
No other person is known to have the right to receive or the power to direct the receipt of dividends from, or any proceeds from the sale of, the common stock beneficially owned by the Reporting Person.
Not applicable.
The information set forth in Item 6 in the Initial Schedule 13D is incorporated herein by reference. The information set forth in Item 3 and Item 4 above is incorporated herein by reference.
Not applicable.